10-Q quarterly report · filed Oct 30, 2026

IRADIMED CORP (IRMD) Q3 2026 10-Q Quarterly Report

Short answer

IRADIMED CORP (IRMD) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $24M (up 14.2% year over year) with net income of $7M.

Q3 2026 key financials · XBRL

Revenue
$24M
+14.2% YoY · +18.3% QoQ
Net income
$7M
+16.7% YoY · +24.7% QoQ
Operating margin
33.6%
Gross margin
76.3%
EPS (diluted)
$0.51
+18.6% YoY · +24.4% QoQ

Source: XBRL data from the IRADIMED CORP (IRMD) Q3 2026 10-Q on SEC EDGAR. USD.

IRADIMED CORP Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $24.2M, up 14% YoY from $21.2M, driven by devices, disposables and international sales
  • Vital signs monitoring revenue $8.0M, up from $6.9M, strongest product growth
  • Gross margin 76% vs 78% YoY, pressured by initial new-product production inefficiencies
  • Net margin 26.9% vs 26.3% YoY, with net income $6.5M vs $5.6M
  • Cash $63.3M vs $51.2M; operating cash flow $21.2M vs $19.0M, financing outflow $8.0M from higher dividends
  • Fiscal 2026 outlook: higher revenue and operating expenses, with tariff, supply-chain and geopolitical uncertainty remaining headwinds

Risk Factors

  • No material changes from risks described in the 2025 Annual Report
  • Unknown or currently immaterial risks could materially adversely affect business, financial condition, or future results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other IRADIMED CORP quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.